Compare Dicks Sporting Goods Inc (DKS) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs GSK plc — how do they compare? Dicks Sporting Goods Inc trades at $136.65 (market cap $13.26B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 6.9× Dicks Sporting Goods Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and GSK plc for 93 Days on average.
| DKS | GSK | |
|---|---|---|
Market Cap | $13.26B | $91.88B |
Volume | 2,292,035 | 7,730,529 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $61.18 |
52-Week Low | $121.15 | $43.24 |
Typical Hold Time | 19 Days | 93 Days |
Enterprise Value | $20.31B | $111.88B |
Dividend Yield | 3.71% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $134.63, up 2.63% today, with a bearish technical signal and mixed earnings history. The stock shows strong profitability with an 18.47% ROE and trades at a discount with a P/E of 14.86 and P/S of 0.57. Recent news highlights a securities class action lawsuit, while the company maintains a solid dividend and analyst consensus remains positive.
The outlook is cautious due to legal overhangs and a recent earnings miss, but the stock offers value with a consensus price target of $153.30. Upside potential exists if the company navigates litigation and maintains operational strength, though risks from competitive pressures and macroeconomic factors persist.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
